

# PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes 1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

# Wodnosday January 10, 2024, 12:00 PM, 1:30 PM

	wednesday, January 10, 2024 – 12.00 m	1 – 1.30 I WI
Present:	Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Chris Grace Robinson (CHC Participant)	stopher Hughes, Dr. Kolin Good, Dr. Carla Huitt,
Absent:	Dr. Mahmood Usman, Dr. Venkateswara Davuluri	
Non-Voting Members:	Amy Nowacki (Pharmacy), Jason Skaria (Pharmacy Manager), Rhonda Montesano (Pharmacy), Evan Sebastian (Pharmacy), George Kimbrow (Clinical Policy Coodinator), Shalyn Kline (Pharmacy), Heather Clarke (Director of Case Management)	
Call to Order:	The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:03 PM.	
Adjourned:	The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:16 PM.	
<b>Next Meeting:</b>	Wednesday, April 10, 2024 – 12:00 PM	
<b>Submitted By:</b>	Shalyn Kline (PHW Pharmacy)	
Committee Chair:	Shalyn Kline, PharmD	<b>Date:</b> 04/10/2024

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\(\xi\)1137 (b)).



Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Jason Skaria called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	State name of new member and title or state OR No new introductions			Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.  Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	<ul><li>i. Voting and vote totals</li><li>ii. Tie breaker</li><li>iii. Pennsylvania's Review and Approval Process</li></ul>	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q4_2023. No objections were made.  Motion to approve: Michelle Bennett, RPh Second motion to approve: Jill Schaeffer, RN	Adoption of Q4_2023 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	No old business	No action required or taken.		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).



			& Wellness
A. Policy Submission Status	There are 0 outstanding clinical policies awaiting approval. One policy (PA.CP.PHAR.641 Avacincaptad pegol (Izervay)) was denied due to being added to the Statewide PDL to Macular Degeneration Agents	No action required or taken.	Shalyn Kline
IV. New Business			
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.		Jason Skaria
B. Provider Education	A vote was taken for the approval of the Serotonin Syndrome provider education. No objections were made.  Motion to approve: Jill Schaeffer, RN Second motion to approve: Michelle Bennett, RPh	The provider education was Committee approved.	Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational	Shalyn Kline
D. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 9 new policies created, 30 policies had clinically significant change, 55 policies with no significant changes and 2 policies being replaced/retired for Medicaid. No objections, concerns or comments were made.  Motion to approve: Dr. Kolin Good Second motion to approve: Jill Schaeffer, RN  For the Pennsylvania Statewide PDL there were 25 policies that were revised, 2 new policies and 1 retired policy that went into effect 1/8/2024. No vote needed.	The policy revisions were Committee approved.	Shalyn Kline
E. Additional Drug Lists and Policies and	A vote was taken for the approval of the Supplemental Drug List Motion to approve: Dr. Kolin Good	The drug lists revisions were	Shalyn Kline
Procedures	Second motion to approve: Michelle Bennett, RPh		

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\xi137 (b)).



			X WELLIE55
	A vote was taken for the approval of the Specialty Drug List Motion to approve: Dr. Kolin Good Second motion to approve: Jill Schaeffer, RN A vote was taken for the approval of the Extended Day Supply List Motion to approve: Jill Schaeffer, RN Second motion to approve: Michelle Bennett, RPh No vote was taken for the Pharmacy Policy & Procedures, as none	Committee approved.	
F. Highlights of New Medications/ Significant Changes	were updated  Shalyn introduced a new section to P&T covering new drugs and/or significant changes of policies.  Evan spoke about new indication of Opdivo for Child-Pugh Class B and melanoma in the adjuvant setting	No action required or taken.	Shalyn Kline/Evan Sebastian
G. Complaints and Grievances Review	Shalyn stated that there was 0 determinations upheld and 3 overturned and 0 withdrawn during pre-grievance. One of the 3 determinations were for opioids.	No action required or taken.	Shalyn Kline
H. Drug Utilization Review	Shalyn Kline presented the drug utilization review, noted the numbers are for October and November.  FWA – There were 62 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. Two Participants were identified with three or more practices/hospitals prescribing opioids. These are being researched to determine if any action is needed.	No action required or taken.	Shalyn Kline
I. PBM Oversight	Jason Skaria reviewed the Corrective Action Plan and stated that it was closed, but post-CAP there is continuation of monitoring of prior authorization denials, and weekly meetings to address any findings. Jason stated that the overall pass rates were between 92 and 97.73%. The PBM call center and prior authorization metrics were reviewed and it was found that all metrics were met, and that there was only 2 outlier for Turn-Around-Time in the last quarter.	No action required or taken.	Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).



			W WELLIESS
J. Open Forum	Shalyn Kline stated the P&T committee is looking for a Behavioral	Shalyn can be	Shalyn Kline
	Health provider.	emailed with	
		any	
		recommendatio	
		ns	
Adjournment	The meeting was adjourned at 12:16 pm	Meeting	Shalyn Kline
		adjourned	
	Evan Sebastian asked for a motion to adjourn.		
	Motion to adjourn: Dr. Carla Huitt		
	Second motion to adjourn: Michelle Bennett, RPh		

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\xi137 (b)).